<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04287946</url>
  </required_header>
  <id_info>
    <org_study_id>08938</org_study_id>
    <nct_id>NCT04287946</nct_id>
  </id_info>
  <brief_title>Endovascular GSN Ablation in Subjects With HFpEF</brief_title>
  <official_title>Endovascular Ablation of the Greater Splanchnic Nerve in Subjects Having Heart Failure With Preserved Ejection Fraction - First In-human Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Axon Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Axon Therapies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and potential benefits of single-side
      block of a nerve that connects to the intestines, liver and spleen called the &quot;greater
      splanchnic nerve&quot; for the treatments of patients with symptomatic heart failure who have
      normal pumping of the heart. The study will be performed in patients whose heart failure is
      not responding well to standard treatments and remain symptomatic.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Anticipated">February 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite incidence of one or more of the following: major adverse cardiac, cerebrovascular embolic, or renal event (MACCRE)</measure>
    <time_frame>1 month</time_frame>
    <description>Composite incidence of one or more of the following: major adverse cardiac, cerebrovascular embolic, or renal event (MACCRE) through 1-month follow up based on Independent Physician Adjudicator (IPA) assessment:
Cardiovascular death; Embolic stroke; Device or procedure-related adverse cardiac events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change of PCWP with exercise after index procedure ablation as compared to baseline</measure>
    <time_frame>1 month</time_frame>
    <description>Mean change of PCWP with exercise after index procedure ablation as compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of MACCRE, all serious adverse events, all-cause mortality, CV mortality and HF related mortality</measure>
    <time_frame>6 month</time_frame>
    <description>Incidence of MACCRE, all serious adverse events, all-cause mortality, CV mortality and HF related mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in average PCWP as compared to baseline</measure>
    <time_frame>1 month</time_frame>
    <description>Change in average PCWP as compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoint</measure>
    <time_frame>1, 3, 6 months</time_frame>
    <description>Change in the quality of life according to the Kansas City Cardiomyopathy Questionnaire (KCCQ) between baseline and follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary Efficacy Endpoint</measure>
    <time_frame>1, 3, 6 months</time_frame>
    <description>Change in exercise tolerance as measured by the 6 minute walk test (6MWT) between baseline and follow-up</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ablation</intervention_name>
    <description>Ablation of a single-side of the greater splanchnic nerve</description>
    <arm_group_label>Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Chronic heart failure

          -  Transthoracic echocardiographic evidence of diastolic dysfunction

          -  Ongoing stable GDMT HF management and management of potential comorbidities

          -  LVEF &gt; or = 50% in the past 3 months

        Key Exclusion Criteria:

          -  Cardiac resynchronization therapy initiated within the past 6 months

          -  Advanced heart failure

          -  Admission for HF within the past 30 days

          -  Presence of significant valve disease

          -  Mean right atrial pressure (RAP) &gt;20mmHg during hemodynamic screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Levin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Coridea, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda Gregg</last_name>
    <phone>+1 410-371-8165</phone>
    <email>lgregg@axontherapies.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Howard Levin, MD</last_name>
    <phone>+1 201-906-5516</phone>
    <email>hlevin@axontherapies.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nemocnice Na Homolce</name>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Petr Neuzil, Professor</last_name>
      <phone>+420603440254</phone>
      <email>pneuzil@seznam.cz</email>
    </contact>
    <contact_backup>
      <last_name>Stepan Kralovec</last_name>
      <phone>+420777671069</phone>
    </contact_backup>
    <investigator>
      <last_name>Petr Neuzil, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tbilisi Heart and Vascular Clinic</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamaz Shaburishvili, MD, PhD</last_name>
      <phone>+995599502244</phone>
      <email>tamaz_shaburishvili@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Teona Zirakashvili, MD</last_name>
      <phone>+995555291018</phone>
      <email>teonaz@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Tamaz Shaburishvili, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teona Zirakashvili, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nona Okinashvili, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Georgia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2020</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Preserved Ejection Fraction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

